1423162-01-9

Upstream product

• 37159-60-7 3-bromo-5-chloro-[1,2,4]thiadiazole 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 1423161-78-7 N-(3-bromo-1,2,4-thiadiazol-5-yl)-N-(4-methoxybenzyl)-1-methyl-3-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-1H-indole-6-sulfonamide 
• 1450923-25-7 N-(3-bromo-1,2,4-thiadiazol-5-yl)-4-[2-chloro-4-(trifluoromethyl)phenyl]-N-(4-methoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide 
• 1450923-26-8 4-(2-chloro-4-(trifluoromethyl)phenyl)-N-(3-cyano-1,2,4-thiadiazol-5-yl)-N-(4-methoxybenzyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide 

Relevant academic research and scientific papers

HETEROARYL SODIUM CHANNEL INHIBITORS

The present invention provides compounds of Formula I or II, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.